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Antipyretic Therapy in Critically Ill Septic Patients:
A Systematic Review and Meta-Analysis
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Objective: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults.
Data Sources: Literature searches were implemented in Ovid
Medline, Embase, Scopus, Cumulative Index of Nursing and
Allied Health Literature, Cochrane Central Register of Controlled
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Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov
through February 2016.
Study Selection: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment,
mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with
neurologic injury, or healthy volunteers. Criteria were applied by
two independent reviewers.
Data Extraction: Two reviewers independently extracted data
and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute
ventilation. Randomized and observational studies were analyzed
separately.
Data Synthesis: Eight randomized studies (1,507 patients) and
eight observational studies (17,432 patients) were analyzed.
Antipyretic therapy did not reduce 28-day/hospital mortality in
the randomized studies (relative risk, 0.93; 95% CI, 0.77–1.13;
I2 = 0.0%) or observational studies (odds ratio, 0.90; 95% CI,
0.54–1.51; I2 = 76.1%). Shock reversal (relative risk, 1.13; 95%
CI, 0.68–1.90; I2 = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61–2.09; I2 = 61.0%) were
also unchanged. Antipyretic therapy decreased body temperature
(mean difference, –0.38°C; 95% CI, –0.63 to –0.13; I2 = 84.0%),
but not heart rate or minute ventilation.
Conclusions: Antipyretic treatment does not significantly improve
28-day/hospital mortality in adult patients with sepsis. (Crit Care
Med 2017; 45:806–813)
Key Words: acetaminophen; antipyretics; fever; mortality; sepsis

O

ver 1 million patients are hospitalized with sepsis
annually in the United States, and sepsis is the leading cause of death in critically ill patients (1). Fever,
a common sign of infection, occurs in approximately 40% of
critically ill septic patients at some point during their ICU stay
(2, 3). It is an extremely complex physiologic response with
potentially beneficial and harmful effects in septic patients.
Fever boosts several aspects of innate and adaptive immunity,
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inhibits microorganism growth, slows viral replication, and
augments antibiotic efficacy (4–8). In animal models, artificially raising core body temperature leads to improved survival
and lower infectious burden (9, 10). However, fever generation also raises the metabolic rate, increases oxygen consumption, and can adversely affect cardiac function (11–13). In
septic patients, who are vulnerable to malperfusion and tissue hypoxia, this physiologic expense could be particularly
detrimental.
Despite the potential benefits of fever in patients with sepsis,
treatment with antipyretic therapies is common in the ICU. In a
recent international survey of ICU practitioners in 23 countries,
greater than 80% of respondents reported controlling fever in
critically ill patients most or all of the time (14). Data supporting this practice, however, remain inconclusive because of limited sample sizes and lack of reproducibility of study results. In
fact, some studies have suggested that antipyresis in critically ill
septic patients may be harmful (15–17). The majority of prior
meta-analyses of the effect of antipyretic therapy in the critically
ill have not focused on septic patients (18–20). Because antipyretic therapy may impact infected and noninfected patients
differently (16), conclusions from these studies are difficult to
interpret. Furthermore, methodologic limitations in previous
evaluations of antipyretic therapy in sepsis render the question
of optimal fever management in this population unclear (21).
The objective of this meta-analysis was to evaluate the effect
of antipyretic therapy on mortality in critically ill septic patients.
Secondary aims included assessing the impact of fever control
on the acquisition of nosocomial infections, shock reversal, and
physiologic variables such as body temperature, heart rate, and
minute ventilation. The primary hypothesis was that antipyretic
therapy would not improve mortality in septic patients.

MATERIALS AND METHODS
This meta-analysis was conducted and reported in accordance
to the Preferred Reporting Items for Systematic Reviews and
Meta-Analysis and Meta-Analysis of Observational Studies in
Epidemiology guidelines (Supplemental Digital Content 1,
http://links.lww.com/CCM/C421) (22, 23). The study protocol (Supplemental Digital Content 2, http://links.lww.com/
CCM/C422) was developed prior to initiation of the search
strategy and has been registered on PROSPERO (registration
number: CRD42016037622). Ethical approval from the human
research protection office was not required.
Literature Search and Study Selection
Published literature was electronically searched by two medical librarians (A.C.H., S.A.F.) for the concepts of sepsis, fever,
antipyretics, and physical cooling in adults. These strategies
were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane
Database of Systematic Reviews, Cochrane Central Register of
Controlled Trials, NHS Economic Evaluation Database, and
ClinicalTrials.gov between January 1946 and February 2016.
Full search strategies are provided in Supplemental Digital
Content 3 (http://links.lww.com/CCM/C423).
Critical Care Medicine

Two authors (A.M.D., E.T.M.) independently screened titles
and abstracts for potentially eligible studies. These included
observational or randomized studies evaluating mortality in
septic patients treated with and without antipyretic therapy.
The full list of inclusion and exclusion criteria is available in
Supplemental Digital Content 4 (http://links.lww.com/CCM/
C424). Studies of antipyretic therapy that included both septic and nonseptic patients were included if mortality data were
provided for the subgroup of septic patients. If these data were
not reported, authors were contacted via electronic mail to
request it. The authors (A.M.D., E.T.M.) also reviewed bibliographies of included articles and performed a hand search
of critical care–related journals to identify additional studies.
Abstracts from critical care–related meetings (full list provided
in the protocol) from 2008 to 2015 were searched to identify
any unpublished literature. Any article identified by either
screener as being potentially eligible was reviewed in full.
Following the initial screening, full articles were independently reviewed by two authors (A.M.D., B.M.F.) with
application of the same inclusion and exclusion criteria.
Disagreements regarding study inclusion were resolved by
consensus. Studies excluded after full-text review are listed
in Supplemental Table 1 (Supplemental Digital Content 5,
http://links.lww.com/CCM/C425).
Data Extraction
Data on study characteristics, patient characteristics, study
interventions, and outcomes were independently extracted
from each study by two study members (A.M.D., E.A.A.) using
standardized forms created in an online data management system (24). A full list of variables collected is provided in Supplemental Digital Content 2 (http://links.lww.com/CCM/C422).
Primary data reported solely in graphical form were extracted
using an online plot data extraction tool (25). When necessary, authors were contacted to provide missing data. Following extraction, data were compared and disagreements were
resolved by consensus.
Outcomes
The primary outcome was 28-day mortality. Studies reporting
hospital mortality were pooled with those reporting 28-day
mortality. Secondary outcomes included “early” mortality
(defined as mortality on or prior to day 14 after enrollment or
within the ICU), frequency of acquisition of nosocomial infections, frequency of shock reversal, and mean changes in body
temperature, heart rate, and minute ventilation with antipyretic
treatment. A priori, the decision was made to analyze 28-day and
14-day mortality separately based on observations of different
mortality rates for these different follow-up periods (26, 27).
For randomized trials, postintervention physiologic values were
pooled for meta-analysis rather than the pre- to postchange in
those values because no study provided measures of dispersion
for the pre- to postintervention changes. This was considered to
be a valid approach based on the assumption that in randomized trials, the differences in mean final values are similar to the
differences in changes of these values (28).
www.ccmjournal.org
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Quality Assessment
For randomized trials, study quality was assessed independently
by two reviewers (A.M.D., E.A.A.) using the Cochrane Collaboration Risk of Bias Tool with standardized criteria for evaluating
bias in seven domains (29). Quality of observational studies was
evaluated with the Newcastle-Ottawa Scale (NOS), a 9-point
scale assessing bias in the areas of patient selection, comparability, exposure, and outcome (30). Disagreements were resolved
by a third reviewer (B.M.F.). A priori, it was decided that randomized studies with a high or unclear risk of bias in less than
two domains or observational studies with an NOS score greater
than 7 would be considered to be high quality.
Data Analysis
Observational and randomized studies were analyzed separately, as recommended by expert opinion (31), using STATA/

Figure 1. Flowchart of study selection.
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IC 14.1 (StataCorp, College Station, TX). For categorical
outcomes, a relative risk (RR) with 95% CI (for randomized
studies) or odds ratio (OR) with 95% CI (for observational
studies) was calculated for each study. Data were combined
using the DerSimonian and Laird (32) random effects model
and plotted as forest plots. Higgins I2 tests were used to assess
heterogeneity. A random effects model was used even if no
heterogeneity was observed due to limitations of statistical
tests for heterogeneity. For observational studies, adjusted
ORs, if available, were preferentially used in the meta-analysis.
For studies evaluating multiple methods of antipyresis, the
overall OR for any type of antipyresis was used in the metaanalysis. However, if an overall OR was not reported, ORs
for each method of antipyresis were included separately. For
continuous outcomes, weighted mean differences were calculated using a random effects model for continuous outcomes.
For continuous data reported
as median and interquartile
range, mean and sd were estimated using previously published methods (33). A p value
less than 0.05 was considered
statistically significant.
Publication
bias
was
assessed using funnel plots
and Egger test. Extended
funnel plots were created to
graphically display the effect
size and se combinations
needed for an additional randomized trial to change the
results of the meta-analysis
(34, 35). Simulation methods
were used to create a graph
demonstrating the power
achieved by an additional randomized trial to change the
results of the meta-analysis at
different sample sizes up to a
maximum of 30,000 patients
(36, 37).
Stratified analyses were
conducted for the primary
outcome by the type of intervention, duration of treatment, and primary goal of
the study (evaluation of
anti-inflammatory treatment
or evaluation of fever treatment). Predefined subgroup
analyses for the primary outcome were performed for the
subset of studies with a low
risk of bias and for the subset of patients with fever and
septic shock.
May 2017 • Volume 45 • Number 5
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RESULTS
Details regarding the literature search and study selection are
shown in Figure 1. A total of 16 studies (eight randomized
studies and eight observational studies) met eligibility criteria
(15, 16, 26, 27, 38–49). Study characteristics are shown in Supplemental Table 2 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425).
Randomized Trials
The randomized studies enrolled a total of 1,531 patients
(1,507 patients included in analysis of the primary outcome).
Patient characteristics and outcome data for the individual trials are shown in Supplemental Tables 3 and 4 (Supplemental
Digital Content 5, http://links.lww.com/CCM/C425). Risk of
bias assessments are shown in Supplemental Table 5 (Supplemental Digital Content 5, http://links.lww.com/CCM/C425).
Five studies had a low risk of bias.
Results of the meta-analyses for the primary and secondary outcomes are listed in Table 1. Four studies (1,198 patients)
reported 28-day mortality with a pooled RR of 0.93 (95% CI,
0.77–1.13; I2 = 0.0%) comparing antipyretic therapy to control.
The remaining four studies reported hospital mortality; adding
this data to the analysis (1,507 total patients) resulted in a pooled
RR of 0.93 (95% CI, 0.79–1.09; I2 = 0.0%) (Fig. 2). Subgroup
analyses of 28-day/hospital mortality in febrile patients (RR,
0.96; 95% CI, 0.80–1.14; I2 = 0.0%) and patients with shock
(RR, 0.91; 95% CI, 0.74–1.11; I2 = 0.0) yielded similar results.
Stratified analyses by type of therapy and treatment goal also did
not differ significantly from that of the aggregate data (Table 1).
Analyses of secondary outcomes (Table 1) showed a significant decrease in early mortality (RR, 0.68; 95% CI, 0.49–0.92;
I2 = 0.0%) with antipyretic therapy. Postintervention body temperature was also significantly lower (mean difference, –0.38°C;
95% CI, –0.63 to –0.13; I2 = 84.0%) in patients treated with
antipyretics. Stratified analysis of postintervention body temperature by type of intervention showed that physical cooling
and nonsteroidal anti-inflammatory drugs (NSAIDs) lowered
body temperature (mean difference, –0.80°C; 95% CI, –1.06
to –0.54 and mean difference, –0.59°C; 95% CI, –1.16 to –0.03;
I2 = 85.4%) more effectively than acetaminophen (mean difference, –0.14°C; 95% CI, –0.37 to 0.10; I2 71.3%). However, only
one study used physical cooling as the primary antipyretic intervention. Postintervention heart rate and minute ventilation were
not significantly different between the groups. The frequency of
nosocomial infections and shock reversal were also unchanged
(forest plots shown in Supplemental Figs. 1–3, Supplemental
Digital Content 5, http://links.lww.com/CCM/C425).
Publication bias was not evident (Egger test, p = 0.60)
(Supplemental Fig. 4, Supplemental Digital Content 5, http://
links.lww.com/CCM/C425). The extended funnel plot, which
graphically demonstrates the combinations of effect size and
se that would be required for an additional study to change the
results of this meta-analysis to support a 28-day/hospital mortality benefit with antipyretic therapy, is shown in Figure 3.
Supplemental Figure 5 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425) shows the power curve generated
Critical Care Medicine

from simulation-based sample size calculations. To achieve a
power of 80% to change the results of this meta-analysis, an
additional study would require a total sample size of approximately 29,000 patients.
Observational Studies
Eight observational studies were deemed eligible. Supplemental Tables 6 and 7 (Supplemental Digital Content 5, http://
links.lww.com/CCM/C425) describe the patient characteristics
and results of the quality assessments. Six studies were high
quality; two, low quality.
A total of 2,058 septic patients (six studies) were included
in the analysis of 28-day/hospital mortality; 15,374 septic
patients (two studies) were included in the analysis of early
mortality. Outcome data for the individual studies, including adjusted and unadjusted ORs for mortality, are shown
in Supplemental Table 8 (Supplemental Digital Content 5,
http://links.lww.com/CCM/C425). The pooled OR for 28-day/
hospital mortality was 0.90 (95% CI, 0.54–1.51; I2 = 76.1%)
(Fig. 2). The pooled OR for early mortality was 0.22 (95% CI,
0.004–13.14; I2 = 86.7%) (Supplemental Fig. 1, Supplemental
Digital Content 5, http://links.lww.com/CCM/C425). Other
secondary outcomes were not reported in a sufficient number
of studies to be analyzed. No specific antipyretic method was
significantly associated with mortality benefit, and stratification by study quality did not yield results that differed from
the overall pooled OR (Table 1). Publication bias was not evident (Egger test, p = 0.54). (Supplemental Fig. 4, Supplemental
Digital Content 5, http://links.lww.com/CCM/C425).

DISCUSSION
Despite lack of evidence showing benefit of antipyretic therapy in septic patients, treatment of fever is ubiquitous in the
ICU (14). This meta-analysis was undertaken to inform clinical practice by assessing outcomes associated with antipyretic
therapy. The results demonstrate that, while associated with a
reduction in body temperature, antipyretic therapy does not
confer a 28-day/hospital mortality benefit in septic patients.
Secondary outcomes, including shock reversal and acquisition of nosocomial infections, were also unaffected by antipyretic treatments. Consistency in results was demonstrated
across study design as well as in a priori subgroup and stratified analyses. Furthermore, the extended funnel plot analysis
suggests that these results are likely to be robust to the impact
of an additional trial in the future; none of the existing studies generated an effect size-se combination that could change
the pooled RR to favor antipyretic treatment. Additionally,
simulation analysis showed that to achieve a reasonable power
to change the meta-analysis results, an additional trial would
need to enroll tens of thousands of patients. Based on the sample sizes and enrollment durations of the existing multicenter
studies, a trial of this size seems unfeasible.
Interestingly, early mortality (occurring within 14 d or
during ICU stay) was significantly lower in patients treated
with antipyretic therapy in the randomized studies. This outcome was analyzed separately from 28-day/hospital mortality
www.ccmjournal.org
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TABLE 1.

Summary of Meta-Analysis Results
Randomized Studies

No. of Sample
Studies Size

Analysis

Relative Risk
(95% CI) or Mean
Difference
(95% CI)

Observational Studies

P

No. of Sample
I2, % Studies Size

OR (95% CI)

P

I2, %

Primary outcome
28-d/hospital mortality

8

1,507

0.93 (0.79–1.09)

0.36

0.0

6

  28-d mortality

4

1,198

0.93 (0.77–1.13)

0.49

0.0

—

  Febrile patients

5

1,341

0.96 (0.80–1.14)

0.60

0.0

4

   Patients with shock

2

493

0.91 (0.74–1.11)

0.34

0.0

—

5

1,238

0.93 (0.76–1.12)

0.43

0.0

5

Early mortality (≤ 14 d/ICU)

4

960

0.68 (0.49–0.92)

0.01

0.0

2

Frequency of nosocomial
infections

3

684

1.13 (0.61–2.09)

0.69 61.0

—

—

—

—

—

Shock reversal

3

232

1.13 (0.68–1.90)

0.63 51.6

—

—

—

—

—

Postintervention
temperature (°C)

8

1,510 –0.38 (–0.63 to –0.13) < 0.003 84.0

—

—

—

—

—

Postintervention heart rate
(beats/min)

5

594

0.18 42.9

—

—

—

—

—

Postintervention minute
ventilation (L/min)

3

514 –0.10 (–1.15 to 0.94)

0.85

0.0

—

—

—

—

—

  Acetaminophen

3

753

0.93 (0.68–1.40)

0.90

0.0

5d

2028 0.81 (0.46–1.42)

  NSAID

4

554

0.94 (0.68–1.31)

0.72 17.4

1

606 2.61 (1.11–6.12)

0.03

  Physical cooling

1

200

0.88 (0.65–1.19)

0.40

2

636 0.20 (0.00–10.91)

0.43 85.5

  Anti-inflammatory treatment

5

594

0.92 (0.66–1.28)

0.61 15.4

1

292 0.48 (0.25–0.92)

0.03

  Fever treatment

3

913

0.93 (0.74–1.18)

0.55

0.0

5

1,766 1.00 (0.57–1.75)

0.99 75.7

  ≥ ICU length of stay

2

713

1.01 (0.70–1.46)

0.95

0.0

2

1,287 1.37 (0.75–2.50)

0.31 77.1

   < ICU length of stay

6

794

0.91 (0.77–1.08)

0.29

0.0

4

771 0.51 (0.26–0.98)

0.05 47.6

  Acetaminophen

3

756 –0.14 (–0.37 to 0.10)

0.26 71.3

—

—

—

—

—

  NSAID

4

554 –0.59 (–1.16 to –0.03)

0.04 85.4

—

—

—

—

—

  Physical cooling

1

200 –0.80 (–1.06 to –0.54)< 0.001 —

—

—

—

—

—

a

  High-quality studies

b

2,058 0.90 (0.54–1.51)
—

—

1160 0.59 (0.32–1.07)
—

—

2028 0.99 (0.62–1.60)

0.70 76.1
—

—

0.08 48.5
—

—

0.98 74.0

Secondary outcomes

c

–4.2 (–10.2 to 1.9)

15,374 1.35 (1.15–1.59) < 0.001 0.0

Stratified analyses
28-d/hospital mortality
by intervention type

—

0.46 74.6
—

28-d/hospital mortality
by treatment goal
—

28-d/hospital mortality
by treatment duration

Postintervention temperature
by intervention type

NSAID = nonsteroidal anti-inflammatory drug, OR = odds ratio.
a
Memiş et al (41) excluded from analysis (100% mortality in both arms).
b
Randomized studies with a high or unclear risk of bias in less than two domains on the Cochran Collaboration Risk of Bias Tool or observational studies with a
Newcastle-Ottawa Scale score greater than 7 were considered to be high quality.
c
Niven et al (42) excluded from analysis (0 nosocomial infections in septic patients in both arms).
d
The two studies by Mohr et al (46, 47) were analyzed in the acetaminophen subgroup due to the reported low use of nonsteroidal anti-inflammatory drugs in
those studies.
Dashes indicate insufficient data to analyze.
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of the metabolic burden typically associated with elevated
body temperature (50). This
meta-analysis shows that
although antipyretic therapy
is effective in decreasing
body temperature, heart rate
and minute ventilation are
less affected. Also, antipyresis did not improve mortality
in the subgroup of patients
with septic shock, who presumably would be the most
likely to benefit from a reduction in metabolic burden.
These results suggest that the
potential physiologic benefit
of antipyretic therapies may
be overstated and does not
translate into improvement
B
in outcomes.
Definitions
of
fever
ranged from a body temperature of 38.0°C to 38.4°C in
the randomized studies and
from 37.3°C to 39.5°C in the
observational studies. The
larger range of fever definitions in the observational
studies may have contributed
(along with other factors
such as variations in study
design, patient population,
and analysis techniques) to
the greater heterogeneity
observed in the meta-analysis
results. Of note, the observaFigure 2. Results of meta-analysis for 28 days per hospital mortality in (A) randomized studies and (B)
tional study with the highest
observational studies. A relative risk (RR) or odds ratio (OR) less than 1 favors antipyretic therapy. The size of the
threshold for fever treatment
grey box corresponds to weight in the random effects analysis. NSAID = nonsteroidal anti-inflammatory drug.
(39.5°C) demonstrated the
most substantial improvebecause several studies reported 14-day/ICU mortality rates ment in 28-day/hospital mortality with antipyretic therapy
that differed from those at later time points (26, 27). The (44). The implication of this finding is unclear, though, because
importance of improved early mortality, though, is question- of this study’s small sample size, methodologic limitations, and
able as a patient-centered outcome, and this finding should not unique method of physical cooling (continuous venovenous
influence clinical practice. One hypothesis for the decrease in hemofiltration).
early, but not later, deaths is that fever treatment blunts the
This meta-analysis has important limitations. Many of studimmunologic benefit of hyperthermia leading to increased
ies included in the analysis were not designed primarily to evalnosocomial infections later in the hospital course. The results uate the clinical effect of fever treatment but rather the effect of
of this meta-analysis demonstrated no significant differences
specific anti-inflammatory actions of the interventions being
in the acquisition of nosocomial infections among patients studied. Thus, both febrile and afebrile patients were enrolled,
who did and did not receive antipyretic therapy. Analysis of
and administration of other antipyretics beyond the specific
this outcome, however, included only three studies, so evidence therapy being studied was not controlled. To address this
is limited. This may be an area for future study.
limitation, analysis of the primary outcome was stratified by
Proponents of fever treatment advocate that the chief ben- the goal of the study (evaluation of anti-inflammatory treatefit of antipyretic therapy in critically ill patients is a reduction
ment vs evaluation of fever treatment) and a subgroup analysis

A
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CONCLUSIONS
Antipyretic treatment does not significantly improve 28-day/
hospital mortality in adult patients with sepsis. Additional
studies are unlikely to be powered sufficiently to change this
conclusion.
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Figure 3. Extended funnel plot demonstrating the effect size and se
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